Have you considered a non-viral approach? Maxcyte’s Flow Electroporation® technology leverages a fundamental property of cells – the reversible permeability of membranes in the presence of an electrical pulse – to deliver molecules such as nucleic acids and proteins, advancing the development of innovative cell therapies from concept to clinic. Learn more about our non-viral transfection platform: https://lnkd.in/egppa2f7
MaxCyte, Inc.
Biotechnology
Rockville, Maryland 8,387 followers
Let's Build Better Cells Together
About us
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Our Vision: Together, we maximize the potential of cells to improve lives. Our Mission: We build trust with our customers, and together we leverage best-in-class technology and expertise to solve the toughest challenges in cell engineering, bringing therapies to patients. Our Core Values: - We value and respect each other, our partners, and patients - We remain undaunted in our commitment to relieving the burden of disease - We dig deep, working together to understand the problem, and always find a way - We stay curious and connected, and never get complacent - We approach each person, each situation with compassion and transparency - We take pride in the excellence of our technology and the expertise we deliver
- Website
-
http://www.maxcyte.com
External link for MaxCyte, Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 1999
- Specialties
- Vaccine Development, Protein Production, Transfection, Cell Therapy, Gene Therapy, Cancer, Immunotherapy, Electroporation, MyExpertPlatform, Tcell, NKcell, Bispecifics, Gene Editing, Cancer Research, Immuno-oncology, Stem Cell, CARMA, Cell Engineering, Biotechnology, Life Sciences, and Innovation
Locations
-
Primary
9713 Key West Ave
Suite 400
Rockville, Maryland 20850, US
Employees at MaxCyte, Inc.
Updates
-
Unlocking the power of DNA transposons for human health! Dive into a newly published article in Cell Press that unveils the profound functional diversity of 130 DNA transposons in human cells, essentially broadening the boundaries of the genome engineering toolbox. Even more significant is the revelation that Mariner2_AG substantially surpasses the lentiviral vector and TE-based vector SB100X in CAR-T therapy for solid and hematological tumors. Their powerful transposition flexibility and evolutionary dynamism in DNA TEs promise a richer toolbox and a brighter future for genetic engineering. https://bit.ly/3WmRXkm
-
Don't miss out on tomorrow's insightful webinar in partnership with Cell & Gene Therapy Insights, where we will explore the nuances of non-viral gene delivery systems for CAR-T manufacturing. There's still time to register, grasp a comprehensive knowledge of diverse non-viral procedures, and learn how to optimize cell engineering efficiencies, viability, and scalability. We're excited to connect with you! Register now at https://bit.ly/3y4VA4U #Cas9 #CRISPR #Webinar #GeneTherapy
-
Allogeneic chimeric antigen receptor (CAR)-T cells are revolutionizing cancer treatment. CAR-T cells, derived from healthy donors, hold immense potential for expanding accessibility to CAR-T therapy. However, allograft rejection has been a challenge, however, scientists have harnessed the power of CRISPR-Cas9 to address this issue. Read an article by BRL Medicine 邦耀生物 published in Cell Press on allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis to learn more. #CRISPR #Cas9 https://bit.ly/4bLbVJK
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
cell.com
-
Use the right cells, right from the start! The MaxCyte ExPERT platform gives you the freedom to use the cell type that makes the most sense for your project. Whatever type of cell you use, MaxCyte electroporation technology delivers virtually any molecule with high efficiency and cell viability for high titer recombinant protein production. MaxCyte’s ExPERT platform enables reproducible transfection of many cell types commonly used for protein production including: #CHO and CHO-derivatives #HEK #Vero #NS0 Experience the advantage of working with the ExPERTs: https://bit.ly/3xUI042
-
Watch on demand as our own Isabel Daher dives into the world of scalable manufacturing of virus-like particles. Discover how VLPs facilitate the delivery of groundbreaking CRISPR-Cas9 Ribonucleoproteins, a significant stride in treating human diseases. Get the details with our poster presentation from the 2024 ASGCT annual meeting. #CRISPR #Cas9 #Ribonucleoproteins #ASGCT2024 #MaxCyte https://bit.ly/45ZamH7
2024 ASGCT Poster - Efficient Scalable Manufacturing of Virus-Like Particles for the Delivery of CRISPR-Cas9 Ribonucleoproteins Using a cGMP-Compliant Electroporation Platform | MaxCyte
https://maxcyte.com
-
MaxCyte invites you to join our webinar in collaboration with Cell & Gene Therapy Insights on the development of non-viral gene delivery platforms for CAR-T manufacturing, on Wednesday, July 24, 2024 at 11:00 am EDT. Register now to gain a deeper understanding of different non-viral processes for CAR-T manufacturing. Explore cutting-edge approaches to CAR expression via knock-ins mediated by homology-directed repair (HDR) or homology-independent targeted insertion (HITI). Learn how to achieve high cell engineering efficiencies, cell viability and scalability, and more. We look forward to connecting with you! #Cas9 #CRISPR https://bit.ly/3y4VA4U
-
It’s truly remarkable how the field of cell and gene therapy is advancing right before our eyes. New therapies are emerging, offering hope for diseases that once had no treatment options. At MaxCyte, we’re dedicated to collaborating with our partners to bring these innovative therapies to patients. How do you envision the future impact of CAR T-cell therapy on treating autoimmune diseases beyond lupus? https://lnkd.in/dhSZKniv
World's first CAR-T cell therapy for a child with lupus
fau.eu
-
The MaxCyte’s ExPERT™ platform is making waves in overcoming lost runs during scale-up. Nitin Kulkarni, PhD, a Senior Field Applications Scientist at MaxCyte, shares valuable insights on enhancing cell viability and recovery. With MaxCyte's Flow Electroporation technology®, Nitin and the team addressed cell viability challenges, ensuring a seamless transition to patient dosing. MaxCyte’s innovative approach empowers researchers and clinicians to navigate the complexities of cell therapy. From discovery to commercialization, the ExPERT™ platform offers best-in-class electroporation technology, scalability, and ongoing support from a global team of experts. If you’re passionate about #CellTherapy and #Innovation, check out our groundbreaking work! https://lnkd.in/gMHFspka
-
Congratulations to StapleBio Inc. Yousuke Katsuda for adding MaxCyte's technology to their labs with their new ExPERT ATx electroporation instrument! This drug discovery startup with a research facility in Okinawa, Japan, develops "Staple Nucleic Acid" molecules that suppress gene expression by targeting repetitive guanine sequences. We are excited to work with the team, and look forward to supporting their work along the way. 沖縄に研究所がある創薬ベンチャー・StapleBio様 (YousukeKatsuda様) にMaxCyteのエレクトロポレーション機器ExPERT ATxを採用していただきました!グアニンの繰り返し配列を手繰り寄せて遺伝子の発現を抑制する"Staple核酸"技術の研究開発を応援しております